Skip to content
Research Article Open access CC BY 3.0

Anticancer Properties of Novel Rhenium Pentylcarbanato Compounds against MDA-MB-468(HTB-132) Triple Node Negative Human Breast Cancer Cell Lines

Carl Parson, Valerie Smith, Christopher Krauss, Hirendra N. Banerjee, Christopher Reilly, Jeanette A. Krause, James M. Wachira, Dipak Giri, Angela Winstead, Santosh K. Mandal

Journal of Pharmaceutical Research International · pp. 362–367 · Published 9 Dec 2013

10.9734/BJPR/2014/4697

Abstract

Aim: To study the efficacy of novel rhenium compounds to treat triple node negative breast cancer. Study Design: Six (6) novel rhenium pentycarbanato compounds (PC1-6) were synthesized and triple node negative breast cancer cell lines HTB-132 and Balb/c mouse kidney cell lines were treated with each of them for 48 hours. The results were analyzed by a common trypan blue cell death assay system and statistically analyzed. Place and Duration: The compounds were synthesized, analyzed and evaluated at the Department of Chemistryof Morgan State University, Baltimore, Maryland and the Pharmaceutical Sciences Department of Elizabeth City State University campus of the University of North Carolina system. Methodology: The novel rhenium compounds were synthesized from one-pot reactions of Re2(CO)10 with the corresponding α-diimine ligands in 1-pentanol.The compounds were characterized spectroscopically. The cell lines were cultured by standard cell culture procedure and treated with each of the six compounds in DMSO for 48 hours with a negative control and a DMSO vehicular control along with a cisplatin positive control.The cytotoxicity was evaluated by standard trypan blue assay and the results were statistically analyzed. Results: The trypan blueassay reveals that these compounds have significant cytotoxicity against MDA-MB-468 (HTB-132) triple node negative breast cancer cell lines and are less nephrotoxic than cisplatin. Conclusion: The novel rhenium compounds PC 1-6 can potentially find applications in the treatment of highly malignant triple node negative breast cancer.

Rhenium pentylcarbonato compounds HTB-132 breast cancer cells cytotoxicity trypan blue assay.

Cited by 19

Core-functionalised Fréchet-type Rhenium metallodendrimers: Insights into their biological activity as anticancer drug leads

J. Powell, Lucy W Macharia, Supratim Biswas · Journal of Organometallic Chemistry · 2025

An Investigation to Study the Role of Novel Rhenium Compounds on Endometrial Uterine Cancer Cell Lines

C. Krauss, Chelsey Aurelius, Kayla Johnston · Journal of Cancer Research Updates · 2020

Design of Rhenium Compounds in Targeted Anticancer Therapeutics.

P. Collery, D. Desmaele, Vijay Kumar Veena · Current pharmaceutical design · 2019

Synthesis and antitumour evaluation of mono- and multinuclear [2+1] tricarbonylrhenium(I) complexes.

D. Giffard, E. Fischer-Fodor, C. Vlad · European journal of medicinal chemistry · 2018

In vitro anticancer activity and in vivo biodistribution of rhenium(I) tricarbonyl aqua complexes

K. Knopf, Brendan L. Murphy, S. N. MacMillan · Journal of the American Chemical Society · 2017

Nuclear Targeting with an Auger Electron Emitter Potentiates the Action of a Widely Used Antineoplastic Drug.

Sebastian Imstepf, Vanessa Pierroz, P. Raposinho · Bioconjugate chemistry · 2015

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

19

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.